The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study

阿帕蒂尼 医学 肝细胞癌 内科学 联合疗法 胃肠病学 不利影响 肿瘤科 酪氨酸激酶抑制剂 实体瘤疗效评价标准 肝癌 无进展生存期 癌症 化疗 临床研究阶段
作者
Zeran Yang,Guang Chen,Ye Cui,Xiao Guo-wen,Ting Su,Jianan Yu,Zhiyuan Zhang,Yanjing Han,Kai-Lan Yang,Long Jin
出处
期刊:Cancer Biology & Therapy [Informa]
卷期号:20 (3): 321-327 被引量:34
标识
DOI:10.1080/15384047.2018.1529099
摘要

As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
亚威完成签到,获得积分10
1秒前
华仔应助fourhairs采纳,获得10
2秒前
材1完成签到 ,获得积分10
2秒前
激情的含巧完成签到,获得积分10
5秒前
霸霸斌完成签到 ,获得积分10
5秒前
hahaha完成签到,获得积分10
6秒前
自信的高山完成签到,获得积分10
8秒前
小皮皮完成签到,获得积分10
10秒前
一一完成签到 ,获得积分10
11秒前
负责的寒梅完成签到 ,获得积分10
12秒前
Stata@R完成签到 ,获得积分10
12秒前
文几完成签到 ,获得积分10
14秒前
阳光的梦寒完成签到 ,获得积分10
15秒前
Tomin完成签到,获得积分10
17秒前
忽忽完成签到,获得积分10
21秒前
诗筠完成签到 ,获得积分10
24秒前
24秒前
24秒前
骑着蚂蚁追大象完成签到,获得积分10
25秒前
刀笔吏完成签到,获得积分10
25秒前
生姜完成签到 ,获得积分10
26秒前
Fx完成签到 ,获得积分10
26秒前
29秒前
King完成签到,获得积分10
30秒前
痴情的从雪完成签到,获得积分10
31秒前
感动清炎完成签到,获得积分10
33秒前
Serein完成签到,获得积分10
33秒前
等待断秋完成签到,获得积分10
34秒前
耿宇航完成签到 ,获得积分10
34秒前
方赫然完成签到,获得积分10
35秒前
弧光完成签到 ,获得积分10
35秒前
rita_sun1969完成签到,获得积分10
36秒前
宇老师完成签到,获得积分10
36秒前
等待孤风完成签到,获得积分10
37秒前
科研通AI2S应助平常亦凝采纳,获得10
39秒前
陈皮完成签到 ,获得积分10
39秒前
粗犷的沛容完成签到,获得积分10
40秒前
文安完成签到,获得积分10
40秒前
人语完成签到 ,获得积分10
41秒前
称心的鑫完成签到 ,获得积分10
44秒前
高分求助中
Spray / Wall-interaction Modelling by Dimensionless Data Analysis 2000
ALA生合成不全マウスでの糖代謝異常の分子機構解析 520
安全防范技术与工程 500
Mathematics and Finite Element Discretizations of Incompressible Navier—Stokes Flows 500
2024 Medicinal Chemistry Reviews 400
Актуализированная стратиграфическая схема триасовых отложений Прикаспийского региона. Объяснительная записка 360
Dictionary of socialism 350
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3192710
求助须知:如何正确求助?哪些是违规求助? 2841781
关于积分的说明 8034694
捐赠科研通 2505466
什么是DOI,文献DOI怎么找? 1338603
科研通“疑难数据库(出版商)”最低求助积分说明 638372
邀请新用户注册赠送积分活动 606929